50TWENTYFOURSEVENBIOPHARMA Issue 3 / October 2025 AXPLORA The use of antibody-drug conjugates (ADCs) has steadily increased in recent years, and the global ADC market is expected to be worth more than $16 billion in 20251. There has also been a considerable increase in private investment in ADCs since 2018, showing a growing interest in their therapeutic and commercial potential2. Although oncology is still the main focus of ADC research and commercialization, ADCs are being explored for new therapeutic areas, including infectious diseases and immunomodulatory applications2. This expansion into new indications will likely drive more ADC use. However, ADC development is not free from challenges, particularly in the critical stages of payload production and bioconjugation. Overcoming them is crucial for ensuring efficient, costeffective production and delivering these life-saving treatments to patients. Challenges of ADC payload production and bioconjugation ADC development hurdles show how difficult it is to get the balance right between therapeutic efficacy and patient safety. The inherent potency of the payloads themselves in a key aspect. These cytotoxic agents, designed to kill or to inhibit replication of cells selectively, have to be synthesized and handled with exceptionally high precision. Containment and environmental control during manufacturing protect workers and prevent unintended contamination. Maintaining the payload’s structural integrity and stability throughout the complex conjugation process adds even more complexity, requiring an understanding of chemical interactions and degradation pathways. The bioconjugation process, where the potent payload is linked to the antibody, has its own obstacles. Achieving a consistent drug-to-antibody ratio (DAR) is a constant challenge, as variations in DAR can dramatically affect the efficacy and safety profile of the ADC. Controlling the exact site of conjugation on the antibody is also critical, as this can change the ADC’s pharmacokinetic properties and target binding. The linker, the molecular bridge between the antibody and the payload, must be engineered for optimal stability in circulation but also designed to release the payload efficiently when the affected microenvironment is reached. This delicate balance requires sophisticated linker chemistry and a lot of in vitro and in vivo testing. Also, the antibody
RkJQdWJsaXNoZXIy MjY2OTA4MA==